First-line Esophageal Carcinoma Study With Chemo vs. Chemo Plus Pembrolizumab (MK-3475-590/KEYNOTE-590)



Status:Active, not recruiting
Conditions:Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:4/5/2019
Start Date:July 25, 2017
End Date:August 22, 2021

Use our guide to learn which trials are right for you!

A Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial of Pembrolizumab (MK-3475) in Combination With Cisplatin and 5-Fluorouracil Versus Placebo in Combination With Cisplatin and 5-Fluorouracil as First-Line Treatment in Subjects With Advanced/Metastatic Esophageal Carcinoma (KEYNOTE-590)

The purpose of this trial is to evaluate efficacy and safety of pembrolizumab plus cisplatin
and 5-fluorouracil (5-FU) chemotherapy versus placebo plus cisplatin and 5-FU chemotherapy as
first-line treatment in participants with locally advanced or metastatic esophageal
carcinoma.

The primary efficacy hypotheses are that both progression-free survival (PFS), according to
Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and determined by blinded
independent central review, and overall survival (OS) are superior with pembrolizumab plus
chemotherapy compared with placebo plus chemotherapy in all participants as well as
participants whose tumors are programmed cell death-ligand 1 (PD-L1)-positive.


Inclusion Criteria:

- Has histologically- or cytologically-confirmed diagnosis of locally advanced
unresectable or metastatic adenocarcinoma or squamous cell carcinoma of the esophagus
or advanced/metastatic Siewert type 1 adenocarcinoma of the esophagogastric junction
(EGJ)

- Has measurable disease per RECIST 1.1 as determined by the local site
investigator/radiology assessment

- Eastern Cooperative Group (ECOG) performance status of 0 to 1

- Can provide either a newly obtained or archival tissue sample for PD-L1 by
immunohistochemistry analysis

- Female participants of childbearing potential must have a negative urine or serum
pregnancy test within 72 hours prior to randomization and be willing to use an
adequate method of contraception (e.g. abstinence, intrauterine device, diaphragm with
spermicide, etc.) for the course of the study through 120 days after the last dose of
study treatment and up to 180 days after last dose of cisplatin

- Male participants of childbearing potential must agree to use an adequate method of
contraception (e.g. abstinence, vasectomy, male condom, etc.) starting with the first
dose of study treatment through 120 days after the last dose of study treatment and up
to 180 days after last dose of cisplatin, and refrain from donating sperm during this
period

- Has adequate organ function

Exclusion Criteria:

- Has locally advanced esophageal carcinoma that is resectable or potentially curable
with radiation therapy (as determined by local investigator)

- Has had previous therapy for advanced/metastatic adenocarcinoma or squamous cell
cancer of the esophagus or advanced/metastatic Siewert type 1 adenocarcinoma of the
EGJ

- Has had major surgery, open biopsy, or significant traumatic injury within 28 days
prior to randomization, or anticipation of the need for major surgery during the
course of study treatment

- Has a known additional malignancy that is progressing or requires active treatment.
Exceptions include early-stage cancers (carcinoma in situ or Stage 1) treated with
curative intent, basal cell carcinoma of the skin, squamous cell carcinoma of the
skin, in situ cervical cancer, in situ breast cancer that has undergone potentially
curative therapy, and in situ or intramucosal pharyngeal cancer

- Has known active central nervous system metastases and/or carcinomatous meningitis.

- Has an active autoimmune disease that has required systemic treatment in past 2 years

- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy
(in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of
immunosuppressive therapy within 7 days prior to the first dose of study treatment, or
has a history of organ transplant, including allogeneic stem cell transplant

- Has a history of (non-infectious) pneumonitis that required steroids or has current
pneumonitis, or has an active infection requiring systemic therapy

- Is pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the study, starting with the screening visit through 120 days
after the last dose of study medication and up to 180 days after last dose of
cisplatin

- Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1),
anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory
T-cell receptor or has previously participated in a pembrolizumab (MK-3475) clinical
trial

- Has severe hypersensitivity (≥ Grade 3) to any study treatment (pembrolizumab,
cisplatin, or 5-FU) and/or any of its excipients

- Has a known history of active tuberculosis (TB; Mycobacterium tuberculosis) or human
immunodeficiency virus (HIV) infection

- Has known history of or is positive for hepatitis B or hepatitis C

- Has received a live vaccine within 30 days prior to the first dose of study treatment

- Has had radiotherapy within 14 days of randomization. Participants who received
radiotherapy >14 days prior to randomization must have completely recovered from any
radiotherapy-related AEs/toxicities
We found this trial at
13
sites
660 S Euclid Ave
Saint Louis, Missouri 63110
(314) 362-5000
Phone: 314-747-6268
Washington University School of Medicine Washington University Physicians is the clinical practice of the School...
?
mi
from
Saint Louis, MO
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
(716) 845-2300
Phone: 716-845-4922
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
?
mi
from
Buffalo, NY
Click here to add this to my saved trials
1924 Alcoa Highway
Knoxville, Tennessee 37920
Phone: 865-305-8780
?
mi
from
Knoxville, TN
Click here to add this to my saved trials
22 S Greene St
Baltimore, Maryland 21201
(410) 328-8667
Phone: 410-328-7450
University of Maryland Medical Center Founded in 1823 as the Baltimore Infirmary, the University of...
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
Boston, Massachusetts 02115
Phone: 617-632-5960
?
mi
from
Boston, MA
Click here to add this to my saved trials
1640 Avenida Pueyrredón
Buenos Aires, C1118
Phone: +541148232574
?
mi
from
Buenos Aires,
Click here to add this to my saved trials
5841 S Maryland Ave
Chicago, Illinois 60637
(773) 702-1000
Phone: 773-702-7596
University of Chicago Medical Center The University of Chicago Medicine has been at the forefront...
?
mi
from
Chicago, IL
Click here to add this to my saved trials
Cleveland, Ohio 44012
Phone: 216-844-6003
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
2799 West Grand Boulevard
Detroit, Michigan 48202
Phone: 313-916-1784
?
mi
from
Detroit, MI
Click here to add this to my saved trials
Los Angeles, California
Phone: 909-724-7423
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
New York, New York 10021
Phone: 646-962-3080
?
mi
from
New York, NY
Click here to add this to my saved trials
Pittsburgh, Pennsylvania 15232
Phone: 412-235-1020
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Westwood, Kansas 66205
Phone: 913-588-1886
?
mi
from
Westwood, KS
Click here to add this to my saved trials